Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 28,680 Shares

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) CEO Sharon Mates sold 28,680 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $74.46, for a total transaction of $2,135,512.80. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $79,696,697.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sharon Mates also recently made the following trade(s):

• On Wednesday, August 21st, Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock traded up $0.12 during midday trading on Friday, hitting $74.48. The company's stock had a trading volume of 268,108 shares, compared to its average volume of 973,190. Intra-Cellular Therapies, Inc. has a 1-year low of $45.50 and a 1-year high of $84.89. The company has a 50-day moving average price of $74.93 and a two-hundred day moving average price of $71.07. The company has a market cap of $7.86 billion, a price-to-earnings ratio of -64.16 and a beta of 1.01.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The business's quarterly revenue was up 45.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.45) EPS. Sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kapitalo Investimentos Ltda bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter valued at approximately $26,000. Headlands Technologies LLC acquired a new stake in Intra-Cellular Therapies during the 1st quarter worth approximately $32,000. Signaturefd LLC boosted its position in Intra-Cellular Therapies by 85.7% during the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 239 shares during the period. Fidelis Capital Partners LLC acquired a new stake in Intra-Cellular Therapies during the 1st quarter worth approximately $53,000. Finally, Summit Securities Group LLC acquired a new stake in Intra-Cellular Therapies during the 2nd quarter worth approximately $56,000. 92.33% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ITCI has been the topic of several analyst reports. Mizuho raised their price target on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, June 21st. UBS Group decreased their price target on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald lifted their price objective on shares of Intra-Cellular Therapies from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. lifted their target price on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, Canaccord Genuity Group lifted their target price on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a "buy" rating in a research note on Thursday, June 20th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $97.00.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.